Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total transaction of $91,003.65. Following the transaction, the director now directly owns 7,218,414 shares in the company, valued at approximately $57,386,391.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock opened at $8.84 on Friday. The company’s fifty day simple moving average is $9.97 and its 200-day simple moving average is $9.16. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.80 and a 52 week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of research analyst reports. TD Cowen began coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, KeyCorp upped their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $12.75.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth $26,000. National Bank of Canada FI lifted its holdings in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after buying an additional 1,500 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock valued at $40,000 after buying an additional 2,817 shares during the last quarter. First Horizon Advisors Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $47,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Recursion Pharmaceuticals by 25.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after acquiring an additional 2,050 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.